How genetic code and arginylation control cell movement
Regulation of cell migration by nucleotide coding sequence and arginylation
This work explores how a cell's genetic code and a protein tag called arginylation change cell movement in ways that matter for cancer spread and heart tissue repair.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11285389 on NIH RePORTER |
What this research studies
Researchers will use lab-grown cells, protein biochemistry, and genetically modified mice to see how small differences in actin's nucleotide sequence and the addition of an arginylation tag affect cell movement. The team focuses on N-terminal arginylation of β-actin and how this modification responds to external signals at the leading edge of moving cells. Experiments combine molecular measurements, cell imaging, and mouse models of tissue remodeling to connect the molecular events to processes like wound healing, heart remodeling, and cancer metastasis. Results are meant to identify molecular steps that could be targeted to slow harmful cell migration or improve repair.
Who could benefit from this research
Good fit: People with cancers that tend to spread (metastatic disease) or with heart conditions involving tissue remodeling would be most likely to benefit from follow-up clinical studies based on this work.
Not a fit: Patients with conditions unrelated to cell movement, such as many metabolic disorders or acute infections, are unlikely to receive direct benefit from this molecular research.
Why it matters
Potential benefit: If successful, this could point to new molecular targets to block cancer spread or improve tissue repair after heart injury.
How similar studies have performed: Prior basic and animal studies have linked actin regulation to cell motility and arginylation to actin function, but translating these molecular findings into therapies is still an early and largely untested step.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Kashina, Anna S — University of Pennsylvania
- Study coordinator: Kashina, Anna S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.